The European Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is poised for significant growth, projected to reach approximately USD 94.94 billion by 2035, up from USD 49.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.59% during this period.
This expansion is largely driven by the increasing demand for personalized therapies, particularly in the realm of cell and gene therapies, alongside the complexities of biologics development. The market is also influenced by strategic initiatives to enhance local manufacturing capabilities, addressing the rising prevalence of chronic diseases and the need for specialized oncology treatments. Furthermore, advancements in biotechnology and the adoption of innovative manufacturing techniques, including continuous manufacturing and single-use systems, are crucial factors propelling market growth.
European CDMOs are transitioning from traditional manufacturing roles to becoming strategic partners in innovation, capable of managing complex biologics and advanced therapies. This evolution is further supported by a growing emphasis on AI-enabled manufacturing and regional supply chain resilience, which are expected to attract long-term investments in the sector. The market is also witnessing a shift towards high-value therapies, such as antibody-drug conjugates and mRNA vaccines, as firms integrate end-to-end services from development to commercial manufacturing.
However, the sector faces challenges, notably in aseptic processing, where stringent regulatory requirements coincide with a shortage of skilled professionals in key markets like Germany and the UK. This talent gap poses risks of operational delays and limits the capacity of manufacturing facilities, highlighting the need for a robust workforce to meet regulatory compliance and demand. Overall, the European pharmaceutical CDMO market is at a pivotal juncture, with opportunities for growth tempered by significant operational challenges.